Jing Liu1,2, Qi Zhu3, Jing Han4, Hui Zhang1, Yuan Li1,2, Yanyun Ma2,5, Hengdong Ji6, Dongyi He3, Jianxin Gu4, Xiaodong Zhou7, John D Reveille7, Li Jin1,2, Hejian Zou8,9, Shifang Ren10, Jiucun Wang11,12,13. 1. State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China. 2. Human Phenome Institute, Fudan University, Shanghai, China. 3. Institute of Arthritis Research, Shanghai Academy of Chinese Medical Sciences, Guanghua Integrative Medicine Hospital, Shanghai, China. 4. Department of Biochemistry and Molecular Biology, Key Laboratory of Glycoconjugate Research Ministry of Public Health, School of Basic Medical Sciences, Fudan University, Shanghai, China. 5. Ministry of Education Key Laboratory of Contemporary Anthropology, Department of Anthropology and Human Genetics, School of Life Sciences, Fudan University, Shanghai, China. 6. Division of Rheumatology, Taizhou People's Hospital, Taizhou, Jiangsu Province, China. 7. Division of Rheumatology and Clinical Immunogenetics, The University of Texas-McGovern Medical School, Houston, TX, USA. 8. Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China. hjzou@fudan.eud.cn. 9. Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China. hjzou@fudan.eud.cn. 10. Department of Biochemistry and Molecular Biology, Key Laboratory of Glycoconjugate Research Ministry of Public Health, School of Basic Medical Sciences, Fudan University, Shanghai, China. shifangren@fudan.edu.cn. 11. State Key Laboratory of Genetic Engineering, Collaborative Innovation Center for Genetics and Development, School of Life Sciences, Fudan University, Shanghai, China. jcwang@fudan.edu.cn. 12. Human Phenome Institute, Fudan University, Shanghai, China. jcwang@fudan.edu.cn. 13. Institute of Rheumatology, Immunology and Allergy, Fudan University, Shanghai, China. jcwang@fudan.edu.cn.
Abstract
OBJECTIVES: MRI is an important tool for evaluating inflammation levels and assessing treatment response in patients with ankylosing spondylitis (AS). However, it is expensive and requires experienced physicians. The goal of this study was to identify a biomarker correlated with the MRI score. METHODS: A total of 558 spondyloarthritis (SpA) patients including 527 AS patients, 10 psoriasis (PsA) patients, and 21 non-radiographic SpA (nr-SpA) patients and 725 controls were enrolled for the studies. Plasma IgG galactosylation (IgG-Gal) level was measured by mass spectrometry. Clinical indexes such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and C-reactive protein (CRP) were measured in all AS patients. MRIs and X-rays were obtained from 65 AS patients who were followed up for 6 months. RESULTS: The IgG-Gal ratio was twice as high in the AS patients compared with the controls. It correlated with inflammation indices which is evaluated by MRI according to SPARCC. (Pearson coefficient/p value was 0.6/7E10-6). In addition, AS patients with a higher IgG-Gal ratio at baseline tended to show greater improvement in inflammation scores by MRI both in 3-month follow-up and 6-month follow-up. CONCLUSION: The IgG-Gal ratio was significantly increased in AS patients. In clinical care, it may be used as a potential biomarker for diagnosis in the future. Key Points • IgG galactosylation level was abnormal in SpA patients. • IgG galactosylation level was associated with MRI indices.
OBJECTIVES: MRI is an important tool for evaluating inflammation levels and assessing treatment response in patients with ankylosing spondylitis (AS). However, it is expensive and requires experienced physicians. The goal of this study was to identify a biomarker correlated with the MRI score. METHODS: A total of 558 spondyloarthritis (SpA) patients including 527 AS patients, 10 psoriasis (PsA) patients, and 21 non-radiographic SpA (nr-SpA) patients and 725 controls were enrolled for the studies. Plasma IgG galactosylation (IgG-Gal) level was measured by mass spectrometry. Clinical indexes such as Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and C-reactive protein (CRP) were measured in all AS patients. MRIs and X-rays were obtained from 65 AS patients who were followed up for 6 months. RESULTS: The IgG-Gal ratio was twice as high in the AS patients compared with the controls. It correlated with inflammation indices which is evaluated by MRI according to SPARCC. (Pearson coefficient/p value was 0.6/7E10-6). In addition, AS patients with a higher IgG-Gal ratio at baseline tended to show greater improvement in inflammation scores by MRI both in 3-month follow-up and 6-month follow-up. CONCLUSION: The IgG-Gal ratio was significantly increased in AS patients. In clinical care, it may be used as a potential biomarker for diagnosis in the future. Key Points • IgG galactosylation level was abnormal in SpA patients. • IgG galactosylation level was associated with MRI indices.
Authors: Mirna Šimurina; Noortje de Haan; Frano Vučković; Nicholas A Kennedy; Jerko Štambuk; David Falck; Irena Trbojević-Akmačić; Florent Clerc; Genadij Razdorov; Anna Khon; Anna Latiano; Renata D'Incà; Silvio Danese; Stephan Targan; Carol Landers; Marla Dubinsky; Dermot P B McGovern; Vito Annese; Manfred Wuhrer; Gordan Lauc Journal: Gastroenterology Date: 2018-01-06 Impact factor: 22.682
Authors: Vernon F Schabert; Crystal Watson; George J Joseph; Paige Iversen; Chakkarin Burudpakdee; David J Harrison Journal: J Manag Care Pharm Date: 2013-10
Authors: M Rudwaleit; R Landewé; D van der Heijde; J Listing; J Brandt; J Braun; R Burgos-Vargas; E Collantes-Estevez; J Davis; B Dijkmans; M Dougados; P Emery; I E van der Horst-Bruinsma; R Inman; M A Khan; M Leirisalo-Repo; S van der Linden; W P Maksymowych; H Mielants; I Olivieri; R Sturrock; K de Vlam; J Sieper Journal: Ann Rheum Dis Date: 2009-03-17 Impact factor: 19.103
Authors: M Rudwaleit; D van der Heijde; R Landewé; J Listing; N Akkoc; J Brandt; J Braun; C T Chou; E Collantes-Estevez; M Dougados; F Huang; J Gu; M A Khan; Y Kirazli; W P Maksymowych; H Mielants; I J Sørensen; S Ozgocmen; E Roussou; R Valle-Oñate; U Weber; J Wei; J Sieper Journal: Ann Rheum Dis Date: 2009-03-17 Impact factor: 19.103
Authors: M Rudwaleit; A G Jurik; K-G A Hermann; R Landewé; D van der Heijde; X Baraliakos; H Marzo-Ortega; M Ostergaard; J Braun; J Sieper Journal: Ann Rheum Dis Date: 2009-05-18 Impact factor: 19.103